Pharmacokinetic interaction between a Chinese herbal formula Huosu Yangwei oral liquid and apatinib in vitro and in vivo. (13th April 2020)

• Record Type: Journal Article
• Authors: Fang, Sheng-Quan; Huang, Jian; Zhang, Feng; Ni, Hong-Mei; Chen, Qi-Long; Zhu, Jun-Ran; Fu, Zhi-Chao; Zhu, Liang; Hao, Wei-Wei; Ge, Guang-Bo
• Is Part Of: Journal of pharmacy and pharmacology. Volume 72:Number 7(2020)
• Page Start: 979
• Page End: 989
• Publication Date: 2020-04-13
• Subjects: apatinib -- cytochrome P450 enzymes -- Huosu Yangwei oral liquid -- pharmacokinetic interaction; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.13268
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objectives: This study aimed to evaluate the inhibitory effects of Huosu Yangwei oral liquid (HSYW) on cytochrome P450 enzymes (CYPs) and to investigate whether this herbal medicine could modulate the pharmacokinetic behaviour of the co-administered CYP-substrate drug apatinib. Methods: Cytochrome P450 enzymes inhibition assays were conducted in human liver microsomes (HLM) by a LC-MS/MS method for simultaneous determination of the oxidative metabolites of eight probe substrates for hepatic CYPs. The modulatory effects of HSYW on the oxidative metabolism of apatinib were investigated in both HLM and rat liver microsomes (RLM). The influences of HSYW on the pharmacokinetic behaviour of apatinib were investigated in rats. Key findings: Huosu Yangwei oral liquid inhibited all tested CYPs in human liver preparations, with the IC50 values ranged from 0.3148 to 2.642 mg/ml. HSYW could also inhibit the formation of two major oxidative metabolites of apatinib in liver microsomes from both human and rat. In-vivo assays demonstrated that HSYW could significantly prolong the plasma half-life of apatinib by 7.4-fold and increase the AUC0–inf (nm ·h) of apatinib by 43%, when HSYW (10 ml/kg) was co-administered with apatinib (10 mg/kg) in rats. Conclusions: Huosu Yangwei oral liquid could inhibit mammalian CYPs and modulated the metabolic half-life of apatinib both in vitro and in vivo .